A retrospective analysis of patients receiving intermediate-risk chemotherapy protocols showed that secondary prophylaxis with G-CSF was independent of the disease status, metastatic vs. early or solid vs. hematological malignancies [14]. This evidence concerns the gene CSF3 and hematologic disorder.